KalVista Pharmaceuticals, Inc.·4

Nov 26, 6:47 PM ET

Audhya Paul K. 4

4 · KalVista Pharmaceuticals, Inc. · Filed Nov 26, 2025

Insider Transaction Report

Form 4
Period: 2025-11-21
Audhya Paul K.
CHIEF MEDICAL OFFICER
Transactions
  • Exercise/Conversion

    Common Stock

    2025-11-21+6,250132,127 total
  • Exercise/Conversion

    Common Stock

    2025-11-22+5,000137,127 total
  • Sale

    Common Stock

    2025-11-24$13.45/sh5,296$71,236131,831 total
  • Exercise/Conversion

    Restricted Stock Unit

    2025-11-216,25081,250 total
    Common Stock (6,250 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2025-11-225,00050,000 total
    Common Stock (5,000 underlying)
Footnotes (3)
  • [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  • [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  • [F3]1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date.

Documents

1 file
  • 4
    form4-11262025_111148.xmlPrimary